Guardant partners with Quest to widen access to Shield cancer test

5 hours ago 1

• Healthcare

• Comments

• Guardant Health (NASDAQ:GH) and Quest Diagnostics (NYSE:DGX) announced a partnership on Wednesday to broaden the availability of the former’s blood-based non-invasive cancer screening test Shield in the U.S.
• Under the multi-year partnership, healthcare providers served by Quest (NYSE:DGX) will

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. Guardant partners with Quest to widen access to Shield cancer test